Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.

Ronald M. Bukowski, William Sharfman, S. Murthy, +7

PubMed

ImmunologyRecombinant Interleukin 2PathologyImmunoeditingRil-2-expanded Tils +18

Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.

G. Thomas Budd, B Osgood, Barbara P. Barna, +7

PubMed

ImmunotoxicologyImmunologyPathologyMalignant MelanomaImmune System +17

Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.

G. Thomas Budd, S. Murthy, James H. Finke, +6

Journal of Clinical Oncology

Open Window Thoracostomy: Modern Update of an Ancient Operation

Karl Reyes, David P. Mason, S. Murthy, +2

The Thoracic and Cardiovascular Surgeon

Phase I Trial of Recombinant Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Lung Cancer: Clinical and Immunologic Effects

Ronald M. Bukowski, S. Murthy, Denise McLain, +7

Journal of Immunotherapy

A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma

Ronald M. Bukowski, Go Inoshita, Prasad Yalavarthi, +6

Cancer

Phase I Trial of Cisplatin, WR-2721, and the Murine Monoclonal Antibody R24 in Patients with Metastatic Melanoma

Ronald M. Bukowski, S. Murthy, James H. Finke, +10

Journal of Immunotherapy

Phase Ia-Ib trial of an anti-GD3 monoclonal antibody in combination with interferon-alpha in patients with malignant melanoma.

Caulfield Mj, Barbara P. Barna, S. Murthy, +4

PubMed

ImmunologyImmunoeditingImmunotherapeuticsMalignant MelanomaImmunotherapy +17

Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer

Kumar Rajagopalan, David M. Peereboom, G. Thomas Budd, +5

Investigational New Drugs

UrologyOncologyPhase Ii TrialMedicinePharmacotherapy +3

Phase I trial of natural human interferon beta in metastatic malignancy.

Ronald M. Bukowski, J. Sergi, William Sharfman, +7

PubMed

Metastatic MalignancyImmunotoxicologyMedicineImmunologyPharmacology +12